Pressmeddelande -
Scandinavian Biopharma and Neovii extend and expand their distribution agreement for the transplantation product Grafalon
Scandinavian Biopharma Distribution AB has extended and expanded its distribution agreement with Neovii Pharmaceuticals AG. This collaboration involves an extension of the agreement for the immunosuppressive drug Grafalon (anti-human T-lymphocyte immunoglobulin, ATLG) in Sweden, Norway, and Denmark, and now also includes Finland, thus encompassing all the Nordic countries.
Grafalon is an antibody-based medication that is crucial in suppressing immune reactions during organ and stem cell transplantation. By reducing the risk of organ rejection and graft-versus-host disease (GvHD), Grafalon improves patients' outcomes in transplantations.
Lisa Sandberg, Marketing Manager at Scandinavian Biopharma, enthusiastically states, "The expanded distribution agreement marks an important milestone for the collaboration between the companies. Our collaboration is a key driver for advancing and improving the care and lives of those in need of transplantation."
Björn Sjöstrand, CEO of Scandinavian Biopharma, expresses gratitude for continuing to represent Neovii and to bring Grafalon to more patients in need in the Nordics.
Ämnen
Kategorier
Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.
The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMMDA).
Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.
